AR110149A2 - Composición catártica - Google Patents
Composición catárticaInfo
- Publication number
- AR110149A2 AR110149A2 ARP170103100A ARP170103100A AR110149A2 AR 110149 A2 AR110149 A2 AR 110149A2 AR P170103100 A ARP170103100 A AR P170103100A AR P170103100 A ARP170103100 A AR P170103100A AR 110149 A2 AR110149 A2 AR 110149A2
- Authority
- AR
- Argentina
- Prior art keywords
- hydroxy
- alkyl
- halogen
- hydrogen
- formula
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 8
- 125000003545 alkoxy group Chemical group 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical class 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 150000002431 hydrogen Chemical class 0.000 abstract 5
- 230000000975 bioactive effect Effects 0.000 abstract 3
- -1 13,14-dihydro-16,16-difluoro-prostaglandin E1 compound Chemical class 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 150000002632 lipids Chemical class 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 206010010774 Constipation Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 230000035568 catharsis Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 238000010926 purge Methods 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Composición catártica que es útil para aliviar o prevenir la constipación, y también para purgar el tracto gastrointestinal. La composición comprende una cantidad efectiva para inducir catarsis de lípido bioactivo halogenado que comprende la estructura parcial de fórmula (1). Reivindicación 1: Uso de un lípido bioactivo halogenado caracterizado porque es para preparar una composición catártica que comprende la estructura parcial de fórmula (1) donde B es -CH₂-CH₂-, -CH=CH- o -CºC-; Z es un resto de fórmula (2) ó (3) donde R⁴ y R⁵ son hidrógeno, hidroxi, halógeno, alquilo inferior, alcoxi inferior o hidroxialquilo (inferior), donde R⁴ y R⁵ no son hidroxi y alcoxi inferior al mismo tiempo; X¹ y X² son hidrógeno, alquilo inferior o halógeno, y al menos uno de ellos es halógeno. Reivindicación 8: Uso tal como se describió en la reivindicación 2, caracterizado porque dicho compuesto es un compuesto de 13,14-dihidro-16,16-difluoro-prostaglandina E₁. Reivindicación 11: Un compuesto lípido bioactivo halogenado, caracterizado porque está representado por la fórmula (4) donde L y M son hidrógeno, hidroxi, halógeno, alquilo inferior, hidroxialquilo (inferior) u oxo, donde al menos uno de L y M es un grupo distinto de hidrógeno, y el anillo de cinco miembros puede tener al menos un enlace doble; A es -CH₂OH, -COCH₂OH, -COOH o un derivado funcional de los mismos; B es -CH₂-CH₂-; Z es un resto de fórmula (2) ó (3) donde R⁴ y R⁵ son hidrógeno, hidroxi, halógeno, alquilo inferior, alcoxi inferior o hidroxialquilo (inferior), donde R⁴ y R⁵ no son hidroxi y alcoxi inferior al mismo tiempo; R¹ es un residuo de hidrocarburo alifático inferior o medio bivalente saturado o insaturado, que está insustituido o sustituido por halógeno, alquilo, hidroxi, oxo, arilo o grupo heterocíclico y al menos uno de los átomos de carbono en el hidrocarburo alifático está opcionalmente sustituido por oxígeno, nitrógeno o azufre; X¹ y X² son átomos de halógeno iguales o diferentes; R² es un enlace simple o alquileno inferior; y R³ es alquilo inferior, alcoxi inferior, cicloalquilo (inferior), cicloalquiloxi (inferior), arilo, ariloxi, grupo heterocíclico o grupo heterocíclico-oxi.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29163501P | 2001-05-18 | 2001-05-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110149A2 true AR110149A2 (es) | 2019-02-27 |
Family
ID=23121127
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101832A AR035242A1 (es) | 2001-05-18 | 2002-05-17 | Uso de un lipido bioactivo halogenadopara preparar una composicion catartica y compuesto lipido bioactivo halogenado |
| ARP140104644A AR098744A2 (es) | 2001-05-18 | 2014-12-12 | Composición catártica |
| ARP170103100A AR110149A2 (es) | 2001-05-18 | 2017-11-08 | Composición catártica |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101832A AR035242A1 (es) | 2001-05-18 | 2002-05-17 | Uso de un lipido bioactivo halogenadopara preparar una composicion catartica y compuesto lipido bioactivo halogenado |
| ARP140104644A AR098744A2 (es) | 2001-05-18 | 2014-12-12 | Composición catártica |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US6956056B2 (es) |
| EP (1) | EP1389116B1 (es) |
| JP (1) | JP4597481B2 (es) |
| KR (1) | KR100867295B1 (es) |
| CN (1) | CN1273140C (es) |
| AR (3) | AR035242A1 (es) |
| AT (1) | ATE387204T1 (es) |
| AU (1) | AU2002307725B2 (es) |
| BR (1) | BR0209863A (es) |
| CA (1) | CA2445651C (es) |
| DE (1) | DE60225266T2 (es) |
| DK (1) | DK1389116T3 (es) |
| ES (1) | ES2301681T3 (es) |
| MX (1) | MXPA03010510A (es) |
| NZ (1) | NZ529406A (es) |
| PT (1) | PT1389116E (es) |
| TW (2) | TWI324589B (es) |
| WO (1) | WO2002094274A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI302100B (en) * | 2001-05-02 | 2008-10-21 | Sucampo Ag | Composition for treating drug-induced constipation |
| AR037524A1 (es) | 2001-11-14 | 2004-11-17 | Sucampo Ag | Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion |
| NZ539582A (en) * | 2002-10-23 | 2007-07-27 | Sucampo Ag | Prostaglandin compounds for the treatment of obesity |
| BRPI0317740B8 (pt) * | 2002-12-27 | 2021-05-25 | Sucampo Ag | uso do composto 13,14-diidro-15-ceto-16,16-diflúorprostaglandina e1 |
| US7049319B2 (en) | 2003-09-23 | 2006-05-23 | Semaan Abboud | Colon cleansing composition and method |
| TWI387454B (zh) | 2004-09-02 | 2013-03-01 | 蘇坎波公司 | 治療胃腸道疾病之方法及組成物 |
| US20070071793A1 (en) * | 2005-09-23 | 2007-03-29 | Leon Clark | Cure for prostate enlargement frequency of urination and cancer |
| CA2856675C (en) * | 2006-02-07 | 2016-04-26 | R-Tech Ueno, Ltd. | Prostaglandin derivatives |
| CN102050808B (zh) * | 2009-11-02 | 2014-03-12 | 上海天伟生物制药有限公司 | 一种前列腺素中间体的制备方法 |
| US9545446B2 (en) | 2013-02-25 | 2017-01-17 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
| JP6957610B2 (ja) | 2016-10-06 | 2021-11-02 | スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ | 医薬品用途のための多層ビーズ |
| US10457623B1 (en) * | 2018-07-13 | 2019-10-29 | Chirogate International Inc. | Process for the preparation of Lubiprostone and intermediates thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1396207A (en) * | 1972-04-27 | 1975-06-04 | Upjohn Co | Prostaglandin intermediates and the preparation thereof |
| US3969376A (en) * | 1973-07-20 | 1976-07-13 | The Upjohn Company | 13,14-Dihydro-16-fluoro prostaglandin E1 analogs |
| JPS5037770A (es) * | 1973-07-20 | 1975-04-08 | ||
| US3969379A (en) * | 1975-02-21 | 1976-07-13 | The Upjohn Company | 13,14-Dihydro-16-fluoro prostaglandin A1 analogs |
| US3969381A (en) * | 1975-02-21 | 1976-07-13 | The Upjohn Company | 13,14-Dihydro-16-fluoro prostaglandin B1 analogs |
| GB8305697D0 (en) * | 1983-03-02 | 1983-04-07 | Erba Farmitalia | Pharmaceutical compositions |
| EP0153858A3 (en) * | 1984-02-29 | 1985-12-11 | The Upjohn Company | The therapeutic use of prostaglandins |
| JPH0681728B2 (ja) * | 1987-10-02 | 1994-10-19 | 株式会社上野製薬応用研究所 | 下 剤 |
| GB2210556B (en) * | 1987-10-02 | 1991-07-17 | Ueno Seiyaku Oyo Kenkyujo Kk | The use of 15-keto-16-halo-prostaglandins in cathartic compositions |
| JP2579193B2 (ja) | 1988-07-19 | 1997-02-05 | 小野薬品工業株式会社 | １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体 |
| DE69130586T2 (de) | 1990-05-01 | 1999-06-17 | R-Tech Ueno, Ltd., Osaka | Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten |
| CA2046069C (en) * | 1990-07-10 | 2002-04-09 | Ryuji Ueno | Treatment of inflammatory diseases with 15-keto-prostaglandin compounds |
| ES2093774T3 (es) * | 1991-03-14 | 1997-01-01 | R Tech Ueno Ltd | Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina. |
| JP3183615B2 (ja) * | 1994-06-03 | 2001-07-09 | 株式会社アールテック・ウエノ | 肝・胆道系疾患処置剤 |
| DK0857718T3 (da) * | 1996-06-10 | 2002-12-16 | Sucampo Ag | Endothelinantagonist |
| BR0212233A (pt) * | 2001-08-31 | 2004-10-05 | Sucampo Ag | Abridor de canal de cloreto |
-
2002
- 2002-05-17 AT AT02771715T patent/ATE387204T1/de active
- 2002-05-17 ES ES02771715T patent/ES2301681T3/es not_active Expired - Lifetime
- 2002-05-17 MX MXPA03010510A patent/MXPA03010510A/es active IP Right Grant
- 2002-05-17 EP EP02771715A patent/EP1389116B1/en not_active Expired - Lifetime
- 2002-05-17 TW TW098122730A patent/TWI324589B/zh not_active IP Right Cessation
- 2002-05-17 TW TW091110333A patent/TWI320711B/zh not_active IP Right Cessation
- 2002-05-17 DK DK02771715T patent/DK1389116T3/da active
- 2002-05-17 CA CA2445651A patent/CA2445651C/en not_active Expired - Lifetime
- 2002-05-17 DE DE60225266T patent/DE60225266T2/de not_active Expired - Lifetime
- 2002-05-17 WO PCT/JP2002/004768 patent/WO2002094274A1/en not_active Ceased
- 2002-05-17 CN CNB028101847A patent/CN1273140C/zh not_active Expired - Lifetime
- 2002-05-17 AR ARP020101832A patent/AR035242A1/es not_active Application Discontinuation
- 2002-05-17 NZ NZ529406A patent/NZ529406A/en not_active IP Right Cessation
- 2002-05-17 AU AU2002307725A patent/AU2002307725B2/en not_active Expired
- 2002-05-17 PT PT02771715T patent/PT1389116E/pt unknown
- 2002-05-17 JP JP2002590991A patent/JP4597481B2/ja not_active Expired - Lifetime
- 2002-05-17 KR KR1020037014860A patent/KR100867295B1/ko not_active Expired - Lifetime
- 2002-05-17 BR BR0209863-6A patent/BR0209863A/pt not_active Application Discontinuation
- 2002-05-20 US US10/147,980 patent/US6956056B2/en not_active Expired - Lifetime
-
2005
- 2005-07-28 US US11/190,842 patent/US7459583B2/en not_active Expired - Lifetime
-
2014
- 2014-12-12 AR ARP140104644A patent/AR098744A2/es not_active Application Discontinuation
-
2017
- 2017-11-08 AR ARP170103100A patent/AR110149A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE60225266T2 (de) | 2009-03-19 |
| TW200944210A (en) | 2009-11-01 |
| WO2002094274A1 (en) | 2002-11-28 |
| MXPA03010510A (es) | 2004-03-02 |
| KR100867295B1 (ko) | 2008-11-06 |
| EP1389116A1 (en) | 2004-02-18 |
| ES2301681T3 (es) | 2008-07-01 |
| AR098744A2 (es) | 2016-06-08 |
| CA2445651A1 (en) | 2002-11-28 |
| AU2002307725B2 (en) | 2008-07-10 |
| US20030022933A1 (en) | 2003-01-30 |
| ATE387204T1 (de) | 2008-03-15 |
| AR035242A1 (es) | 2004-05-05 |
| TWI320711B (en) | 2010-02-21 |
| CA2445651C (en) | 2011-08-09 |
| EP1389116B1 (en) | 2008-02-27 |
| US6956056B2 (en) | 2005-10-18 |
| NZ529406A (en) | 2005-09-30 |
| JP2004529960A (ja) | 2004-09-30 |
| DE60225266D1 (de) | 2008-04-10 |
| DK1389116T3 (da) | 2008-06-23 |
| US7459583B2 (en) | 2008-12-02 |
| TWI324589B (en) | 2010-05-11 |
| CN1273140C (zh) | 2006-09-06 |
| PT1389116E (pt) | 2008-04-11 |
| BR0209863A (pt) | 2004-06-08 |
| CN1509176A (zh) | 2004-06-30 |
| US20050261375A1 (en) | 2005-11-24 |
| JP4597481B2 (ja) | 2010-12-15 |
| KR20040020055A (ko) | 2004-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110149A2 (es) | Composición catártica | |
| AR036391A1 (es) | Uso de un compuesto de prostaglandina para preparar una composicion farmaceutica para abrir los canales de cic en un mamifero y compuestos de prostaglandina | |
| NO20044822L (no) | Fortykkede syreblanding og anvendelser derav | |
| JP2008531468A5 (es) | ||
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| RU96100854A (ru) | Производные 2,8-дизамещенных хиназолинона, их таутомеры и соли, фармацевтическая композиция с воздействующей на уровень кгмп и камп активностью | |
| CO5570660A2 (es) | Indazolilpirrolotriazinas c-6 modificadas | |
| ECSP003828A (es) | Antagonistas de neurokinina selectivos | |
| PE20050157A1 (es) | Derivados de n-acil nitrogeno heterociclicos como ligandos del receptor activador del proliferador de peroxisoma (ppar) | |
| ES2188194T3 (es) | 1,8-naftiridin-4(1h)-onas sustituidas como inhibidores de la fosfodiesterasa 4. | |
| AR059571A1 (es) | Derivados de octahidro-pirrolo[3,4-c]pirrol, composiciones farmaceuticas | |
| CL2024000581A1 (es) | Compuestos de 6-aminopirazolopirimidina y su uso médico. | |
| JP2004527567A5 (es) | ||
| CO4750668A1 (es) | Ascomicinas | |
| NO20062617L (no) | Anvendelse av glukosidase inhibitorer for terapi av mucovisidose | |
| CO5140104A1 (es) | Derivados de mevinolina y preparacion farmaceuticas que los contienen | |
| CO5640109A2 (es) | Compuestos triciclicos inhibidores de la farnesisl proteino transferasa y composiciones farmaceuticas que los contienen | |
| KR890014443A (ko) | 신규한 치환 나프타렌 화합물 및 동 화합물을 함유하는 액정조성물 | |
| CO5261527A1 (es) | Eteres del acido benzoico de oxazolidinonas que tienen un substituyente hidroxiacetilpiperazina | |
| NO990578L (no) | Diesel-brennstoff inneholdende oksygenerte forbindelser | |
| JP2004529960A5 (es) | ||
| AR018632A1 (es) | Compuestos derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene, proceso para su preparacion. | |
| AR041720A1 (es) | Derivados de n- benzodioxolilo, n- benzodioxanilo y n- benzodioxepinilarilcarboxamida que pueden usarse para el tratamiento de dislipidemia, y composiciones farmaceuticas que los contienen | |
| AR041080A1 (es) | Compuestos de 5- croman- 5- il- etilamina substituidos y su uso para el tratamiento de glaucoma | |
| AR030277A1 (es) | Composicion promotora de la secrecion biliar y uso de 15-ceto-prostaglandina para producirla |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |